Life sciences tools Specialty Diagnostics segment income margin measures segment income as a percentage of segment revenue under Thermo Fisher Scientific's management reporting definition.
Thermo Fisher reported a 27.7% Specialty Diagnostics segment income margin in the second quarter of 2026, up from 27.0% a year earlier.
Volume leverage and productivity improved conversion
Thermo Fisher attributed the margin increase to favorable volume leverage and strong productivity, partly offset by unfavorable business mix.
That means the margin change reflects more than the segment's 5% organic revenue growth alone.
Preserve the issuer's segment scope
Thermo Fisher's segment income definition and Specialty Diagnostics portfolio should not be normalized into a generic diagnostic-provider margin.
Compare it with Specialty Diagnostics organic revenue growth and Laboratory Products and Biopharma Services segment income margin.
Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.
Part of the Life Sciences Tools & Biopharma Services Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- TMOOpen operating-model research →10 of 10 reviewed concepts in Life Sciences Tools & Biopharma Services EconomicsSegment income conversion4 of 4 bridge concepts supportedContinue through this bridge:Analytical Instruments MarginLab Products & Biopharma MarginLife Sciences Solutions Margin
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare specialty diagnostics margins
Compare segment-income conversion with volume leverage, productivity, business mix, and issuer scope kept explicit.
Explore more topics in the Financial Research Encyclopedia.